Waldenstrom Macroglobulinema-Associated Retinopathy

History of Present Illness The patient is a 61-year-old male who presents with worsening vision in both eyes. Two years prior, at the time of his last dilated exam, he was 20/25 in both eyes. Since that time, he has noticed a gradual decline in vision in both eyes. He has poorly controlled diabetes mellitus type II with a recent hemoglobin A1c of 8.0%. His diabetes is treated with oral medications. He denies any sudden loss of vision, flashing lights, new floaters, or headaches.

[1]  R. Advani,et al.  Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. , 2014, Blood.

[2]  N. Gray,et al.  A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. , 2013, Blood.

[3]  M. Stauch,et al.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.

[4]  N. Munshi,et al.  MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. , 2013, Blood.

[5]  S. Treon,et al.  Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia. , 2008, Investigative ophthalmology & visual science.

[6]  S. Montoto,et al.  Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases , 2001, British journal of haematology.

[7]  A. Mansour,et al.  Paraproteinemic maculopathy. , 2014, Ophthalmology.

[8]  W. Klapper,et al.  The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) , 2009, Leukemia.

[9]  W. Reinhart,et al.  Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenström and multiple myeloma: influence on blood rheology and the microcirculation. , 1992, The Journal of laboratory and clinical medicine.